Inhal Pharma completes ~￥100M Series B financing to accelerate DPI innovation, with a focus on global expansion and new peptide inhalation segments

Recently, Inhal Pharma announced the completion of a nearly 100 million Series B financing round. This round was led by the Beijing Medical and Health Industry Investment Fund, with participation from institutions such as Sunz Fund. The raised capital will be strategically directed toward three key areas: advancing the clinical progress of core pipeline products, building a globally leading peptide inhalation delivery platform, and accelerating the international deployment of innovative products. This initiative aims to comprehensively strengthen Inhal's full-chain competitive advantage in the field of dry powder inhalation (DPI) drug delivery.

Inhal Pharma is a high-tech enterprise focused on the innovation of drug-device combination dry powder inhalation (DPI) delivery systems. It integrates R&D, production, and sales, primarily targeting the development of dry powder inhalation formulations for respiratory and cardiovascular diseases. Inhal has established a closed-loop system spanning laboratory technology, industrial-scale production, and commercial promotion. The successful closing of this financing round not only reflects deep recognition from investors of Inhal's technological capabilities and strategic planning but also marks the company's entry into a new three-dimensional development phase characterized by "accelerated clinical progress, platform upgrade, and global expansion."

•FD4001: A compound dry powder inhaler (DPI) for asthma treatment, which utilizes self-developed spherical agglomeration technology to optimize particle fluidization. Its lung deposition rate exceeds 50%, significantly outperforming conventional DPIs. The product has entered a critical clinical stage and is expected to break the monopoly of international giants such as AstraZeneca and GSK in the high-end DPI market.

• FD4014: A triple-combination DPI for moderate to severe chronic obstructive pulmonary disease (COPD). It employs a proprietary double-blister dry powder inhaler device and multi-component particle synergistic dispersion technology to address challenges in coordinated delivery and stability of triple-combination formulations. The product matches the convenience and efficacy of originator drugs and will further expand Inhal Pharma's portfolio in the respiratory disease field.

• F2008: A modified new drug for the rare disease idiopathic pulmonary fibrosis (IPF). Through drug repurposing and dry powder inhalation delivery, it achieves precise targeting of the pulmonary interstitium. This product is set to fill the global gap in inhalation therapies for IPF. The Investigational New Drug (IND) applications in China and the U.S. are expected to be submitted soon, with the potential to become a best-in-class therapy.

• FD1016: An innovative inhalation drug for weight management. It delivers a triple-target (GLP1/GIP/GCG) polypeptide via dry powder inhalation, entering the bloodstream through the lungs to achieve long-term fat reduction. This approach avoids the pain and wounds associated with subcutaneous injections. Compared to similar oral products, it offers a several-fold increase in bioavailability. It requires no refrigeration and has better stability than traditional injections, positioning it as a first-in-class product.

All four products are developed based on Inhal Pharma's full-chain dry powder inhalation delivery platform. From formulation design and device development to customized production lines, the company maintains full autonomy and control. The development cycle is approximately 3–5 years shorter than the industry average, with significant cost advantages. These products comprehensively address critical clinical needs in asthma, COPD, IPF, and weight management.

In the field of core technological innovation, Ningbo Inhal Pharma has continued to make breakthroughs:

• Iterative Advancements in DPI Technology: Inhal has independently developed innovative dry powder inhaler devices, including disc-blister type, single-use disposable type, and continuous capsule-based inhalers. These innovations address the pain points of traditional devices, such as improper usage, operational inconvenience, and high costs. In parallel, Inhal has developed customized equipment, including ultrafine powder micro-dosing and precision filling systems. These achievements have successfully broken the monopoly held by international giants, significantly reducing costs compared to imported equipment, and have now been implemented for industrial-scale application.

• Development of a Peptide Dry Powder Inhalation Delivery Platform: The newly raised funds will be strategically invested in the research and development of inhalation delivery technologies for peptide-based drugs. This initiative aims to overcome industry challenges such as poor stability and low bioavailability of peptide drugs. Inhal is building an integrated, full-chain platform encompassing peptide molecular design, delivery system development, inhaler-device matching, and industrial-scale validation. This platform targets emerging therapeutic areas such as weight management, anti-aging, and age-related diseases, addressing unmet clinical needs and benefiting a broad patient population.

• Expansion into Nasal Dry Powder Delivery Platform: Inhal has newly established a focus on nasal dry powder delivery technology, concentrating on the treatment of central nervous system (CNS) diseases. By controlling particle size, optimizing formulation design, and improving nasal delivery devices, the platform enables drugs to reach and take effect in the brain via the olfactory region. Screening for drugs targeting neurodegenerative and psychiatric disorders has already been initiated, aiming to fill the technological gap in targeted nasal-to-CNS dry powder delivery globally.

Currently, Inhal Pharma has established a diversified product pipeline covering respiratory diseases, obesity, metabolic disorders, and other therapeutic areas, striving to become a global leader in dry powder inhalation drug delivery innovation.

Inhal Pharma will leverage this financing as a catalyst to initiate international registration and market expansion for its innovative products. On one hand, Inhal will advance the registration, clinical development, and commercialization of its core pipeline in major markets such as Europe and the United States. On the other hand, it will establish a global collaboration network. Through technology licensing, co-development, and other partnership models, Inhal aims to bring its self-developed inhalation formulation technologies and products to the global stage. This effort seeks to break the market monopoly held by international giants in the high-end inhalation segment and contribute to the global advancement of China's inhalation pharmaceutical industry.